Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
trastuzumab-DOTA-Indium-111
- Development stage
- Preclinical
- Lead developer
- Covalab
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Gamma Emitters → Radiopharmaceuticals, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
trastuzumab-DOTA-Indium-111 is a radioimmunoconjugate consisting of the humanized anti-HER2 monoclonal antibody trastuzumab conjugated to the chelating agent DOTA and radiolabeled with the gamma-emitting radioisotope Indium-111 (111In). Developed using Covalab's site-specific enzymatic conjugation technology, CovIsoLink™, this agent is designed for the non-invasive detection and monitoring of HER2-positive tumors, such as breast cancer, via single-photon emission computed tomography (SPECT/CT) imaging. By binding specifically to the extracellular domain of HER2, trastuzumab-DOTA-Indium-111 allows for the visualization of HER2 expression levels and biodistribution in vivo, aiding in patient stratification and therapy selection.
- Other names
- 111In-DOTA-Herceptin111In-DOTA-trastuzumab111In-labeled DOTA-trastuzumabindium (111In) DOTA-trastuzumabindium-111 DOTA-trastuzumabindium111 DOTA-trastuzumabindium 111 DOTA-trastuzumab
02
Targets
ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on trastuzumab-DOTA-Indium-111.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on trastuzumab-DOTA-Indium-111.